---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009957"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:04:59.102096+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# uniQure closes sale of Lexington facility to Genezen for $25M; $40M annual cash burn savings

## Summary
- Sold Lexington, MA manufacturing facility to Genezen for $12.5M in Series C stock and $12.5M convertible note (total $25M).
- Prepaid $50M of $100M Hercules debt; remaining $50M matures Jan 2027; expects $40M annual reduction in cash burn.
- COO Pierre Caloz exits as role eliminated; Amin Abujoub appointed Chief Technical Operations Officer.
- CEO Matt Kapusta joins Genezen board; Genezen to supply HEMGENIX under commercial supply agreement.
- Transaction closed July 22, 2024; uniQure becomes meaningful shareholder in Genezen.

## SEC filing metadata
- accession: 0001558370-24-009957
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837024009957/0001558370-24-009957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837024009957/qure-20240722x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009957
- JSON: https://secwatch.observer/filing/0001558370-24-009957.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009957.txt

## Key facts
- Executive change
  Pierre Caloz was terminated as Chief Operating Officer at uniQure N.V..
  - Action: terminated
  - Role: Chief Operating Officer
  source text: In connection with the closing of the Lexington Transaction, on July 22, 2024, the Company notified Pierre Caloz, the Company’s Chief Operating Officer, that his employment was being terminated consistent with the terms of the employment agreement by and between uniQure biopharma B.V. and Mr. Caloz, dated May 17, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000155837024009957/0001558370-24-009957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.